Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
Population-Pharmakokinetik-/Target-Engagement-Modellierung von tozorakimab bei gesunden Freiwilligen und Patient:innen mit chronisch obstruktiver Lungenerkrankung
British Journal of Clinical Pharmacology · 2024-12 · 90 (12) · 3286-3295
DOI: 10.1111/bcp.16195 ↗Auf einen Blick
Bei 60 mit tozorakimab behandelten Teilnehmenden wurde ein PK/TE-Modell für IL-33/sST2 erstellt. Ab Dosen >90 mg sagte das Modell für alle 3 Dosierfrequenzen eine Inhibition von >95 % voraus.
Fragestellung
Beschreibung der PK-/TE-Beziehung von tozorakimab auf Basis von Phase-1-Biomarkerdaten.
Methode
Mechanistisches Populations-PK/TE-Modell mit Serumdaten von 60 Teilnehmenden; Simulationen für 3 Dosierfrequenzen und 7 Dosen; nichtlineares Mixed-Effects-Modell.
Ergebnisse
Das finale Zwei-Kompartiment-Modell beschrieb die systemische PK und TE von tozorakimab auf Population- und Individualebene. Die mittleren PK-Parameter betrugen für Absorptionsrate 0,48, zentrales Verteilungsvolumen 12,64 L und Clearance 0,87 L/Tag; Bioverfügbarkeit 45 %.
Schlussfolgerung der Autor:innen
Das PK/TE-Modell quantifizierte die Beziehung zwischen PK und systemischer TE von tozorakimab zuverlässig und könnte zur Vorhersage von Dosis-Wirkungs-Beziehungen und zur klinischen Dosisauswahl genutzt werden.
Kernaussagen
- Finales Zwei-Kompartiment-Modell beschrieb PK und TE auf Population- und Individualebene.
- >95 % Inhibition von IL-33/sST2 bei Dosen >90 mg für alle 3 Dosierfrequenzen.
- Bioverfügbarkeit betrug 45 %.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 25.08.2024. Verfasst von Muhammad Waqas Sadiq und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Interleukin-33, Models, Biological, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Themen: COPD
Abstract (Originalsprache)
Aims
This study describes the pharmacokinetic (PK)/target engagement (TE) relationship of tozorakimab, an anti‐interleukin (IL)‐33 antibody, by building a mechanistic population PK/TE model using phase 1 biomarker data.
Methods
The analysis included tozorakimab PK and TE in serum assessed in 60 tozorakimab‐treated participants, including healthy adults and patients with mild chronic obstructive pulmonary disease. Scenarios evaluated three dose frequencies (once every 2, 4 or 6 weeks) administered subcutaneously at seven doses of tozorakimab (30, 60, 90, 120, 150, 300 or 600 mg). For each dose, simulations were performed with 5000 virtual individuals to predict systemic TE. Inhibition of IL‐33/soluble ST2 (sST2) complex levels at trough PK at steady state was assessed in each dosing scenario. The PK/TE modelling analyses were performed using a nonlinear mixed‐effect modelling approach.
Results
The final two‐compartment PK model with tozorakimab binding IL‐33 in the central compartment adequately described the systemic PK and TE of tozorakimab at population and individual levels. The mean PK parameter estimates of absorption rate, central volume of distribution and clearance were 0.48 (90% confidence interval [CI]: 0.40–0.59, 1/day), 12.64 (90% CI: 8.60–18.62, L) and 0.87 (90% CI: 0.65–1.16, L/day), respectively. Consistent with the observed value, tozorakimab bioavailability was 45%. For all three dose frequencies, predicted inhibition of systemic IL‐33/sST2 levels was more than 95% at doses greater than 90 mg.
Conclusions
The PK/TE model reliably quantified the relationship between PK and systemic TE of tozorakimab, with potential utility for predicting clinical dose–response relationships and supporting clinical dose selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
- Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
- GxP Testing Lab, Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
- Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
ORCID-Profile: Muhammad Waqas Sadiq, Magnus Åstrand
Förderung
- AstraZeneca
Zitieren
APA
Sadiq, M. W., Yu, H., Åstrand, M., Scott, I. C., Williams, A., Hewitt, L., White, N., Killick, H., Gavala, M., Cohen, E. S., Reid, F., Kell, C., Pandya, H., & Jimenez, E. (2024). Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology, 90(12), 3286-3295. https://doi.org/10.1111/bcp.16195
Vancouver
Sadiq MW, Yu H, Åstrand M, Scott IC, Williams A, Hewitt L, et al. Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology. 2024;90(12):3286-3295. doi:10.1111/bcp.16195
BibTeX
@article{Sadiq2024,
author = {Sadiq, Muhammad Waqas and Yu, Hongtao and Åstrand, Magnus and Scott, Ian C and Williams, Adam and Hewitt, Lisa and White, Nicholas and Killick, Helen and Gavala, Monica and Cohen, E Suzanne and Reid, Fred and Kell, Chris and Pandya, Hitesh and Jimenez, Eulalia},
title = {Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {12},
pages = {3286--3295},
doi = {10.1111/bcp.16195}
}
EUVIMED